105 related articles for article (PubMed ID: 15640616)
1. Irofulven: resurgence for alkylating therapy in cancer?
Dent P; Grant S
Cancer Biol Ther; 2004 Nov; 3(11):1143-4. PubMed ID: 15640616
[No Abstract] [Full Text] [Related]
2. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.
Woynarowski JM; Woynarowska BA; Trevino AV; Salinas R; Herman TS; Waters SJ; Macdonald JR
Cancer Biol Ther; 2004 Nov; 3(11):1137-42; discussion 1143-4. PubMed ID: 15467441
[TBL] [Abstract][Full Text] [Related]
3. Irofulven induces replication-dependent CHK2 activation related to p53 status.
Wang Y; Wiltshire T; Senft J; Reed E; Wang W
Biochem Pharmacol; 2007 Feb; 73(4):469-80. PubMed ID: 17118344
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.
Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM
Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
[TBL] [Abstract][Full Text] [Related]
6. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
Wang W; Waters SJ; MacDonald JR; Roth C; Shentu S; Freeman J; Von Hoff DD; Miller AR
Anticancer Res; 2002; 22(2A):559-64. PubMed ID: 12014623
[TBL] [Abstract][Full Text] [Related]
7. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.
Liang H; Salinas RA; Leal BZ; Kosakowska-Cholody T; Michejda CJ; Waters SJ; Herman TS; Woynarowski JM; Woynarowska BA
Mol Cancer Ther; 2004 Nov; 3(11):1385-96. PubMed ID: 15542777
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy.
Johnson KR; Young KK; Fan W
Clin Cancer Res; 1999 Sep; 5(9):2559-65. PubMed ID: 10499633
[TBL] [Abstract][Full Text] [Related]
9. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
10. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of enantiomers of antitumor irofulven.
McMorris TC; Staake MD; Kelner MJ
J Org Chem; 2004 Feb; 69(3):619-23. PubMed ID: 14750783
[TBL] [Abstract][Full Text] [Related]
12. Morning for Irofulven, What Could be fiNER?
Jiang H; Greenberg RA
Clin Cancer Res; 2021 Apr; 27(7):1833-1835. PubMed ID: 33472911
[TBL] [Abstract][Full Text] [Related]
13. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
Wang W; Waters SJ; MacDonald JR; Von Hoff DD; Strodel WE; Miller AR
Anticancer Res; 2001; 21(3B):1789-94. PubMed ID: 11497260
[TBL] [Abstract][Full Text] [Related]
14. Reaction of irofulven with zinc and acid.
McMorris TC; Moon SS; Kelner MJ
J Nat Prod; 2003 Feb; 66(2):310-2. PubMed ID: 12608875
[TBL] [Abstract][Full Text] [Related]
15. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
[TBL] [Abstract][Full Text] [Related]
16. Irofulven (MGI Pharma).
Baekelandt M
Curr Opin Investig Drugs; 2002 Oct; 3(10):1517-26. PubMed ID: 12431030
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine inhibits colon carcinoma HT-29 cells growth via the Bcl-2/Caspase 3/PARP pathway and G1/S phase.
Li J; Wang Q; Wang Z; Cui N; Yang B; Niu W; Kuang H
Biosci Rep; 2019 May; 39(5):. PubMed ID: 31040202
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues.
McMorris TC; Yu J; Lira R; Dawe R; MacDonald JR; Waters SJ; Estes LA; Kelner MJ
J Org Chem; 2001 Sep; 66(18):6158-63. PubMed ID: 11529745
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
